Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward!

Oral vitamin K antagonists (VKAs), warfarin, have been in routine clinical use for almost 70 years for various cardiovascular conditions. Direct-Acting Oral Anticoagulants (DOACs) have emerged as competitive alternatives for VKAs to prevent stroke in patients with non-valvular atrial fibrillation (A...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelnabi, Mahmoud, Benjanuwattra, Juthipong, Okasha, Osama, Almaghraby, Abdallah, Saleh, Yehia, Gerges, Fady
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960500/
https://www.ncbi.nlm.nih.gov/pubmed/35347478
http://dx.doi.org/10.1186/s43044-022-00259-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960500/
https://www.ncbi.nlm.nih.gov/pubmed/35347478
http://dx.doi.org/10.1186/s43044-022-00259-9

Ejemplares similares